ADXS insider filings

Ayala Pharmaceuticals, Inc. — 11 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-03-06. Screen ADXS transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ADXS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Ayala Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2024-03-064Israel Biotech Fund I, L.P. — Director, 10% owner
Israel Biotech Fund II, L.P. — Director, 10% owner
Israel Biotech Fund GP Partners, L.P. — Director, 10% owner
Israel Biotech Fund GP Partners II, L.P. — Director, 10% owner
I.B.F. Management Ltd. — Director, 10% owner
Option exercise (M): 3,750,000 (derivative) · Option exercise (M): 3,750,000 (derivative) · Option exercise (M): 1,500,000 (derivative) · Option exercise (M): 1,500,000 (derivative) · Option exercise (M): 2,250,000 (derivative) · Option exercise (M): 2,250,000 (derivative)EDGAR
2024-02-124Israel Biotech Fund I, L.P. — Director, 10% owner
Israel Biotech Fund II, L.P. — Director, 10% owner
Israel Biotech Fund GP Partners, L.P. — Director, 10% owner
Israel Biotech Fund GP Partners II, L.P. — Director, 10% owner
I.B.F. Management Ltd. — Director, 10% owner
Option exercise (M): 1,926,221 @ $0.40 · Option exercise (M): 4,237,687 @ $0.40 · Option exercise (M): 3,887,438 @ $0.40 · Option exercise (M): 1,295,813 @ $0.40 · Option exercise (M): 8,437,500 @ $0.40 · Tax withholding (F): 2,707,581 @ $1.25 · +8 moreEDGAR
2023-11-214Israel Biotech Fund I, L.P. — 10% owner
Israel Biotech Fund II, L.P. — 10% owner
Israel Biotech Fund GP Partners, L.P. — 10% owner
Israel Biotech Fund GP Partners II, L.P. — 10% owner
I.B.F. Management Ltd. — 10% owner
Purchase (P) · Purchase (P) · Purchase (P): 2,812,500 (derivative) · Purchase (P): 6,187,500 (derivative) · Purchase (P): 5,625,000 (derivative) · Purchase (P): 6,187,500 (derivative) · +4 moreEDGAR
2023-10-314Israel Biotech Fund I, L.P. — 10% owner
Israel Biotech Fund II, L.P. — 10% owner
Israel Biotech Fund GP Partners, L.P. — 10% owner
Israel Biotech Fund GP Partners II, L.P. — 10% owner
I.B.F. Management Ltd. — 10% owner
Purchase (P): 658,858 @ $0 · Purchase (P): 658,858 @ $0EDGAR
2023-10-234aMoon Growth Fund Limited Partnership — 10% ownerOther (J): 0 @ $0EDGAR
2023-09-294/AIsrael Biotech Fund I, L.P. — 10% owner
Israel Biotech Fund II, L.P. — 10% owner
Israel Biotech Fund GP Partners, L.P. — 10% owner
Israel Biotech Fund GP Partners II, L.P. — 10% owner
I.B.F. Management Ltd. — 10% owner
Purchase (P) @ $1,500,000 · Purchase (P) @ $500,000EDGAR
2023-09-114Israel Biotech Fund I, L.P. — 10% owner
Israel Biotech Fund II, L.P. — 10% owner
Purchase (P) @ $1,500,000 · Purchase (P) @ $500,000EDGAR
2023-01-234SIDRANSKY DAVID — DirectorGrant/award (A): 46 · Grant/award (A): 2,342 (derivative) · Grant/award (A): 2,342 (derivative)EDGAR
2023-01-234GOLDBERG MURRAY A — DirectorGrant/award (A): 3,279 (derivative) · Grant/award (A): 2,342 (derivative) · Grant/award (A): 1,171 (derivative) · Grant/award (A): 1,171 (derivative)EDGAR
2023-01-234Bisker-Leib Vered — DirectorGrant/award (A): 1,639 (derivative) · Grant/award (A): 1,171 (derivative) · Grant/award (A): 1,171 (derivative)EDGAR
2023-01-234Spiegel Robert J. — DirectorGrant/award (A): 3,279 (derivative) · Grant/award (A): 2,342 (derivative) · Grant/award (A): 1,171 (derivative) · Grant/award (A): 1,171 (derivative)EDGAR

Recent 8-K events — Ayala Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-04-198-K/A9.01 — Financial Statements and ExhibitsEDGAR
2024-04-038-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2024-03-298-K2.01 — Completion of Acquisition or Disposition of Assets
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-058-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2024-02-238-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2024-02-098-K3.02 — Unregistered Sales of Equity Securities
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2024-02-068-K1.01 — Entry into a Material Definitive Agreement
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-01-038-K/A9.01 — Financial Statements and ExhibitsEDGAR
2023-10-208-K2.01 — Completion of Acquisition or Disposition of Assets
3.02 — Unregistered Sales of Equity Securities
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2023-09-218-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ADXS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs